The parenteral compounding market size is projected to be worth US$ 1.7 billion in 2023. The market is likely to surpass US$ 4.0 billion by 2033 at a CAGR of 9.1% during the forecast period. The market is influenced by factors such as regulatory compliance, patient needs, and industry collaborations, with the ultimate goal of providing safe and customized medications to patients requiring parenteral administration.
The parenteral compounding market serves a wide range of healthcare settings, including hospitals, clinics, long-term care facilities, and home healthcare. It involves compounding pharmacies, outsourcing facilities, and healthcare professionals specializing in sterile compounding. Moreover, the growing focus on quality control and patient safety drives the demand for specialized parenteral compounding services.
Other Drivers Propelling the Demand for Parenteral Compounding Market include:
Challenges for Companies /Manufacturers in the Parenteral Compounding Market:
Opportunities in the Parenteral Compounding Market Industry:
Latest Trends in the Parenteral Compounding Market:
| Attributes | Details |
|---|---|
| Parenteral Compounding Market Size (2023) | US$ 1.7 million |
| Parenteral Compounding Market Projected Size (2033) | US$ 4.0 billion |
| Value CAGR (2023 to 2033) | 9.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global parenteral compounding market experienced a CAGR of 6.8%, reaching a market size of US$ 1.7 million in 2023.
From 2012 to 2022, the global parenteral compounding market industry witnessed steady growth due to the increased need for sterile medications. Parenteral compounding is crucial for preparing sterile medications, especially for patients who cannot take oral medications. Sterile compound involves the preparation of injectable drugs, intravenous solutions, and other sterile medications has been a significant driver for the growth of the parenteral compound market over the years.
Drug shortage have been a recurring issue in the pharmaceutical industry. During drug shortages, compounding pharmacies play a vital role in to meet patient needs. The ability of compounding pharmacies to fill the haps during drug shortages has contributed to the growth of the parenteral compounding market.
Future Forecast for Parenteral Compounding Market Industry:
Looking ahead, the global parenteral compounding market industry is expected to rise at a CAGR of 9.1% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 4.0 billion by 2033.
The parenteral compounding market industry is expected to continue its growth trajectory from 2023 to 2033 due to increasing demand for personalized medicines. Personalized medicine, which involves tailoring medical treatment to an individual’s specific needs, is gaining momentum. Parenteral compounding plays a crucial role in preparing customized medications to meet individual patient requirements. As personalized medicine continues to evolve, the demand for parenteral compounding services is expected to rise, driving the market
| Country | The United States |
|---|---|
| Market Size (US$ Billion) by End of Forecast Period (2033) | US$ 1.8 billion |
| CAGR % 2023 to End of Forecast (2033) | 7.8% |
The parenteral compounding market industry in the United States is expected to reach a market size of US$ 1.8 billion by 2033, expanding at a CAGR of 7.8%. Due to the increasing demand for personalized medicine. The USA healthcare system places a significant emphasis on personalized medicine, aiming to provide tailored treatment options to individual patients. Parenteral compounding allows healthcare providers to customize medications based on patients' specific needs, such as dosage, formulation, and route of administration. The growing demand for personalized medicine drives the growth of the parenteral compounding market in the USA
| Country | The United Kingdom |
|---|---|
| Market Size (US$ Billion) by End of Forecast Period (2033) | US$ 122.1 million |
| CAGR % 2023 to End of Forecast (2033) | 4.2% |
The parenteral compounding market industry in the United Kingdom is expected to reach a market share of US$ 122.1 million, expanding at a CAGR of 4.2% during the forecast period. The United Kingdom market is projected to growth of the market due to the advancements in compounding technology. Technological advancements in compounding equipment and processes enhance the efficiency, accuracy, and safety of parenteral compounding. The UK market benefits from innovative compounding technologies, such as sterile compounding devices, automated compounding systems, and software solutions that streamline compounding processes. These advancements attract healthcare providers and compounding facilities to invest in modern compounding technologies, driving market growth.
| Country | China |
|---|---|
| Market Size (US$ Billion) by End of Forecast Period (2033) | US$ 95.3 million |
| CAGR % 2023 to End of Forecast (2033) | 17.6% |
The parenteral compounding market industry in China is anticipated to reach a market size of US$ 95.3 million, moving at a CAGR of 17.6% during the forecast period. The parenteral compounding market industry in China is expected to grow prominently due to the increasing prevalence of chronic diseases. China is witnessing an increasing prevalence of chronic diseases, including cardiovascular diseases, diabetes, respiratory diseases, and cancer. These conditions often require specialized treatment regimens, including parenteral medications. The growing patient population with chronic diseases fuels the demand for parenteral compounding services in China.
| Country | Japan |
|---|---|
| Market Size (US$ Billion) by End of Forecast Period (2033) | US$ 230.7 million |
| CAGR % 2023 to End of Forecast (2033) | 12.1% |
The parenteral compounding market industry in Japan is estimated to reach a market size of US$ 230.7 million by 2033, thriving at a CAGR of 12.1%. The market in Japan is predicted to grow because of the growing geriatric population. Japan has a large aging population, which is more susceptible to chronic diseases and complex medication requirements. As older adults often face challenges in swallowing or require specialized dosing, parenteral compounding provides an effective solution for delivering medications. The expanding geriatric population contributes to the increased demand for compounded parenteral medications in the country.
| Country | South Korea |
|---|---|
| Market Size (US$ Billion) by End of Forecast Period (2033) | US$ 12.3 million |
| CAGR % 2023 to End of Forecast (2033) | 11.8% |
The parenteral compounding market industry in South Korea is expected to reach a market size of US$ 12.3 million, expanding at a CAGR of 11.8% during the forecast period. There is a growing demand for personalized medicine in South Korea, with a focus on providing tailored treatment options to individual patients. Parenteral compounding allows healthcare providers to customize medications based on specific patient needs, such as dosage, formulation, and route of administration. The increasing demand for personalized medicine supports the growth of the parenteral compounding market.
Principal Consultant
The hormone replacement therapy (HRT) is dominating the parenteral compounding market industry with a market share of 49.7% in 2022. The growth in unmet demand for HRT in emerging nations, as well as greater knowledge of the treatment of hormone issues, drives pharmaceutical companies to continuously bring new cutting-edge drugs to the global market. Furthermore, the rise in menopause and diseases related with hormone deficiency in developed countries has encouraged manufacturers to produce new products, such as combination therapy solutions, in place of the long-acting parenteral pharmaceuticals that were previously administered on a daily basis.
The adults to dominating the parenteral compounding market with the market share of 54.0% in 2022. Adults often have more complex medication regimens compared to children. They may require multiple medications, higher dosages, or specialized formulations that are not commercially available. Parenteral compounding allows healthcare providers to customize medications specifically tailored to the individual needs of adult patients.
This sector is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must employ smart techniques.
Key Strategies Used by the Participants
To produce innovative goods that increase efficacy, dependability, and cost-effectiveness, businesses make significant investments in research and development. Product innovation enables companies to stand out from the competition while also meeting the shifting needs of their customers.
Strategic alliances and partnerships with other businesses are regularly formed by major players in an industry to take advantage of each other's advantages and expand their market reach. Through such arrangements, businesses may also obtain access to new technologies and markets.
The market for parenteral compounding is rising quickly in developing nations like China and India. To boost their presence in these regions, major companies are expanding their distribution networks and building regional manufacturing sites.
Key companies in the parenteral compounding market routinely employ mergers and acquisitions to strengthen their market positions, broaden their product offerings, and enter new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Parenteral Compounding Market:
The growth potential of the market is 9.1% through 2033.
Stringent regulatory oversight challenges in parenteral compounding.
From 2012 to 2022, the market experienced a CAGR of 6.8%.
High demand for compounded sterile preparations (CSPs) is the key trend.
Focusing on unique manufacturing techniques for industry goals is the key trend.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Recent Product Approvals/Launches
4.3. Regulatory Landscape
4.4. PESTEL Analysis
4.5. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Medical Device Outlook
5.1.3. Global Life Expectancy Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Key Player’s Historic Growth
5.2.2. Growing Advancements in Drug Delivery
5.2.3. Evolution of the Pharmaceutical Industry
5.2.4. Rising Demand for Minimally Invasive Procedures
5.2.5. Increasing Preference For Personalized Medicine
5.2.6. Demand of Immediate Pain Relief
5.2.7. Frequency of Product Approvals
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Therapeutic Area
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By Therapeutic Area, 2012 to 2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033
7.3.1. Pain Management
7.3.2. Hormone Replacement Therapy
7.3.3. Others
7.4. Market Attractiveness Analysis By Therapeutic Area
8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Application, 2012 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033
8.3.1. Adults
8.3.2. Pediatric
8.3.3. Geriatric
8.3.4. Veterinary
8.4. Market Attractiveness Analysis By Application
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
9.1. Introduction
9.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
10.1. Introduction
10.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
10.3.1. By Country
10.3.1.1. USA
10.3.1.2. Canada
10.3.2. By Therapeutic Area
10.3.3. By Application
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Therapeutic Area
10.4.3. By Application
10.5. Country Level Analysis & Forecast
10.5.1. USA Market Analysis
10.5.1.1. .Introduction
10.5.1.2. Market Analysis and Forecast by Market Taxonomy
10.5.1.2.1. By Therapeutic Area
10.5.1.2.2. By Application
10.5.2. Canada Market Analysis
10.5.2.1. Introduction
10.5.2.2. Market Analysis and Forecast by Market Taxonomy
10.5.2.2.1. By Therapeutic Area
10.5.2.2.2. By Application
10.6. Market Trends
10.7. Key Market Participants - Intensity Mapping
10.8. Drivers and Restraints - Impact Analysis
11. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Mexico
11.3.1.3. Argentina
11.3.1.4. Rest of Latin America
11.3.2. By Therapeutic Area
11.3.3. By Application
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Therapeutic Area
11.4.3. By Application
11.5. Country Level Analysis & Forecast
11.5.1. Brazil Market Analysis
11.5.1.1. .Introduction
11.5.1.2. Market Analysis and Forecast by Market Taxonomy
11.5.1.2.1. By Therapeutic Area
11.5.1.2.2. By Application
11.5.2. Mexico Market Analysis
11.5.2.1. Introduction
11.5.2.2. Market Analysis and Forecast by Market Taxonomy
11.5.2.2.1. By Therapeutic Area
11.5.2.2.2. By Application
11.5.3. Argentina Market Analysis
11.5.3.1. Introduction
11.5.3.2. Market Analysis and Forecast by Market Taxonomy
11.5.3.2.1. By Therapeutic Area
11.5.3.2.2. By Application
11.6. Market Trends
11.7. Key Market Participants - Intensity Mapping
11.8. Drivers and Restraints - Impact Analysis
12. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. Germany
12.3.1.2. France
12.3.1.3. Italy
12.3.1.4. UK
12.3.1.5. Spain
12.3.1.6. Russia
12.3.1.7. BENELUX
12.3.1.8. Rest of Europe
12.3.2. By Therapeutic Area
12.3.3. By Application
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Therapeutic Area
12.4.3. By Application
12.5. Country Level Analysis & Forecast
12.5.1. Germany Market Analysis
12.5.1.1. .Introduction
12.5.1.2. Market Analysis and Forecast by Market Taxonomy
12.5.1.2.1. By Therapeutic Area
12.5.1.2.2. By Application
12.5.2. France Market Analysis
12.5.2.1. Introduction
12.5.2.2. Market Analysis and Forecast by Market Taxonomy
12.5.2.2.1. By Therapeutic Area
12.5.2.2.2. By Application
12.5.3. Italy Market Analysis
12.5.3.1. Introduction
12.5.3.2. Market Analysis and Forecast by Market Taxonomy
12.5.3.2.1. By Therapeutic Area
12.5.3.2.2. By Application
12.5.4. UK Market Analysis
12.5.4.1. .Introduction
12.5.4.2. Market Analysis and Forecast by Market Taxonomy
12.5.4.2.1. By Therapeutic Area
12.5.4.2.2. By Application
12.5.5. Spain Market Analysis
12.5.5.1. .Introduction
12.5.5.2. Market Analysis and Forecast by Market Taxonomy
12.5.5.2.1. By Therapeutic Area
12.5.5.2.2. By Application
12.5.6. Russia Market Analysis
12.5.6.1. .Introduction
12.5.6.2. Market Analysis and Forecast by Market Taxonomy
12.5.6.2.1. By Therapeutic Area
12.5.6.2.2. By Application
12.5.7. BENELUX Market Analysis
12.5.7.1. .Introduction
12.5.7.2. Market Analysis and Forecast by Market Taxonomy
12.5.7.2.1. By Therapeutic Area
12.5.7.2.2. By Application
12.6. Market Trends
12.7. Key Market Participants - Intensity Mapping
12.8. Drivers and Restraints - Impact Analysis
13. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. India
13.3.1.2. Thailand
13.3.1.3. Indonesia
13.3.1.4. Malaysia
13.3.1.5. Rest of South Asia
13.3.2. By Therapeutic Area
13.3.3. By Application
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Therapeutic Area
13.4.3. By Application
13.5. Country Level Analysis & Forecast
13.5.1. India Market Analysis
13.5.1.1. .Introduction
13.5.1.2. Market Analysis and Forecast by Market Taxonomy
13.5.1.2.1. By Therapeutic Area
13.5.1.2.2. By Application
13.5.2. Thailand Market Analysis
13.5.2.1. .Introduction
13.5.2.2. Market Analysis and Forecast by Market Taxonomy
13.5.2.2.1. By Therapeutic Area
13.5.2.2.2. By Application
13.5.3. Indonesia Market Analysis
13.5.3.1. Introduction
13.5.3.2. Market Analysis and Forecast by Market Taxonomy
13.5.3.2.1. By Therapeutic Area
13.5.3.2.2. By Application
13.5.4. Malaysia Market Analysis
13.5.4.1. Introduction
13.5.4.2. Market Analysis and Forecast by Market Taxonomy
13.5.4.2.1. By Therapeutic Area
13.5.4.2.2. By Application
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
14. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Therapeutic Area
14.3.3. By Application
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Therapeutic Area
14.4.3. By Application
14.5. Country Level Analysis & Forecast
14.5.1. China Market Analysis
14.5.1.1. .Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Therapeutic Area
14.5.1.2.2. By Application
14.5.2. Japan Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Therapeutic Area
14.5.2.2.2. By Application
14.5.3. South Korea Market Analysis
14.5.3.1. Introduction
14.5.3.2. Market Analysis and Forecast by Market Taxonomy
14.5.3.2.1. By Therapeutic Area
14.5.3.2.2. By Application
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Australia
15.3.1.2. New Zealand
15.3.2. By Therapeutic Area
15.3.3. By Application
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Therapeutic Area
15.4.3. By Application
15.5. Country Level Analysis & Forecast
15.5.1. Australia Market Analysis
15.5.1.1. .Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Therapeutic Area
15.5.1.2.2. By Application
15.5.2. New Zealand Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Therapeutic Area
15.5.2.2.2. By Application
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. GCC Countries
16.3.1.2. Türkiye
16.3.1.3. Northern Africa
16.3.1.4. South Africa
16.3.1.5. Rest of Middle East and Africa
16.3.2. By Therapeutic Area
16.3.3. By Application
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Therapeutic Area
16.4.3. By Application
16.5. Country Level Analysis & Forecast
16.5.1. GCC Countries Market Analysis
16.5.1.1. .Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Therapeutic Area
16.5.1.2.2. By Application
16.5.2. Türkiye Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Therapeutic Area
16.5.2.2.2. By Application
16.5.3. Northern Africa Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Therapeutic Area
16.5.3.2.2. By Application
16.5.4. South Africa Market Analysis
16.5.4.1. Introduction
16.5.4.2. Market Analysis and Forecast by Market Taxonomy
16.5.4.2.1. By Therapeutic Area
16.5.4.2.2. By Application
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Share Analysis of Top Players
17.3. Market Presence Analysis
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Avella Specialty Pharmacy
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Key Financials
18.3.1.4. Sales Footprint
18.3.1.5. SWOT Analysis
18.3.1.6. Strategy Overview
18.3.1.6.1. Marketing Strategy
18.3.1.6.2. Product Strategy
18.3.1.6.3. Channel Strategy
18.3.2. McKesson Corporation
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Key Financials
18.3.2.4. Sales Footprint
18.3.2.5. SWOT Analysis
18.3.2.6. Strategy Overview
18.3.2.6.1. Marketing Strategy
18.3.2.6.2. Product Strategy
18.3.2.6.3. Channel Strategy
18.3.3. Victoria Compounding Pharmacy
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Key Financials
18.3.3.4. Sales Footprint
18.3.3.5. SWOT Analysis
18.3.3.6. Strategy Overview
18.3.3.6.1. Marketing Strategy
18.3.3.6.2. Product Strategy
18.3.3.6.3. Channel Strategy
18.3.4. Vertisis Custom Pharmacy
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Key Financials
18.3.4.4. Sales Footprint
18.3.4.5. SWOT Analysis
18.3.4.6. Strategy Overview
18.3.4.6.1. Marketing Strategy
18.3.4.6.2. Product Strategy
18.3.4.6.3. Channel Strategy
18.3.5. Smith Caldwell Drug Store
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Key Financials
18.3.5.4. Sales Footprint
18.3.5.5. SWOT Analysis
18.3.5.6. Strategy Overview
18.3.5.6.1. Marketing Strategy
18.3.5.6.2. Product Strategy
18.3.5.6.3. Channel Strategy
18.3.6. Sixth Avenue Medical Pharmacy
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Key Financials
18.3.6.4. Sales Footprint
18.3.6.5. SWOT Analysis
18.3.6.6. Strategy Overview
18.3.6.6.1. Marketing Strategy
18.3.6.6.2. Product Strategy
18.3.6.6.3. Channel Strategy
18.3.7. Cantrell Drug Company
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Key Financials
18.3.7.4. Sales Footprint
18.3.7.5. SWOT Analysis
18.3.7.6. Strategy Overview
18.3.7.6.1. Marketing Strategy
18.3.7.6.2. Product Strategy
18.3.7.6.3. Channel Strategy
18.3.8. Clinigen Group
18.3.8.1. Overview
18.3.8.2. Product Portfolio
18.3.8.3. Key Financials
18.3.8.4. Sales Footprint
18.3.8.5. SWOT Analysis
18.3.8.6. Strategy Overview
18.3.8.6.1. Marketing Strategy
18.3.8.6.2. Product Strategy
18.3.8.6.3. Channel Strategy
18.3.9. Dougherty's Pharmacy
18.3.9.1. Overview
18.3.9.2. Product Portfolio
18.3.9.3. Key Financials
18.3.9.4. Sales Footprint
18.3.9.5. SWOT Analysis
18.3.9.6. Strategy Overview
18.3.9.6.1. Marketing Strategy
18.3.9.6.2. Product Strategy
18.3.9.6.3. Channel Strategy
18.3.10. Fagron N.V.
18.3.10.1. Overview
18.3.10.2. Product Portfolio
18.3.10.3. Key Financials
18.3.10.4. Sales Footprint
18.3.10.5. SWOT Analysis
18.3.10.6. Strategy Overview
18.3.10.6.1. Marketing Strategy
18.3.10.6.2. Product Strategy
18.3.10.6.3. Channel Strategy
18.3.11. Fresenius Kabi
18.3.11.1. Overview
18.3.11.2. Product Portfolio
18.3.11.3. Key Financials
18.3.11.4. Sales Footprint
18.3.11.5. SWOT Analysis
18.3.11.6. Strategy Overview
18.3.11.6.1. Marketing Strategy
18.3.11.6.2. Product Strategy
18.3.11.6.3. Channel Strategy
18.3.12. Institutional Pharmacy Solutions
18.3.12.1. Overview
18.3.12.2. Product Portfolio
18.3.12.3. Key Financials
18.3.12.4. Sales Footprint
18.3.12.5. SWOT Analysis
18.3.12.6. Strategy Overview
18.3.12.6.1. Marketing Strategy
18.3.12.6.2. Product Strategy
18.3.12.6.3. Channel Strategy
18.3.13. Lorraine's Pharmacy
18.3.13.1. Overview
18.3.13.2. Product Portfolio
18.3.13.3. Key Financials
18.3.13.4. Sales Footprint
18.3.13.5. SWOT Analysis
18.3.13.6. Strategy Overview
18.3.13.6.1. Marketing Strategy
18.3.13.6.2. Product Strategy
18.3.13.6.3. Channel Strategy
18.3.14. Millers Pharmacy
18.3.14.1. Overview
18.3.14.2. Product Portfolio
18.3.14.3. Key Financials
18.3.14.4. Sales Footprint
18.3.14.5. SWOT Analysis
18.3.14.6. Strategy Overview
18.3.14.6.1. Marketing Strategy
18.3.14.6.2. Product Strategy
18.3.14.6.3. Channel Strategy
18.3.15. Nephron Pharmaceuticals
18.3.15.1. Overview
18.3.15.2. Product Portfolio
18.3.15.3. Key Financials
18.3.15.4. Sales Footprint
18.3.15.5. SWOT Analysis
18.3.15.6. Strategy Overview
18.3.15.6.1. Marketing Strategy
18.3.15.6.2. Product Strategy
18.3.15.6.3. Channel Strategy
18.3.16. Wells Pharmacy Network
18.3.16.1. Overview
18.3.16.2. Product Portfolio
18.3.16.3. Key Financials
18.3.16.4. Sales Footprint
18.3.16.5. SWOT Analysis
18.3.16.6. Strategy Overview
18.3.16.6.1. Marketing Strategy
18.3.16.6.2. Product Strategy
18.3.16.6.3. Channel Strategy
18.3.17. RXQ Compounding Pharmacy
18.3.17.1. Overview
18.3.17.2. Product Portfolio
18.3.17.3. Key Financials
18.3.17.4. Sales Footprint
18.3.17.5. SWOT Analysis
18.3.17.6. Strategy Overview
18.3.17.6.1. Marketing Strategy
18.3.17.6.2. Product Strategy
18.3.17.6.3. Channel Strategy
18.3.18. AmerisourceBergen Corporation
18.3.18.1. Overview
18.3.18.2. Product Portfolio
18.3.18.3. Key Financials
18.3.18.4. Sales Footprint
18.3.18.5. SWOT Analysis
18.3.18.6. Strategy Overview
18.3.18.6.1. Marketing Strategy
18.3.18.6.2. Product Strategy
18.3.18.6.3. Channel Strategy
18.3.19. B. Braun Melsungen AG Company
18.3.19.1. Overview
18.3.19.2. Product Portfolio
18.3.19.3. Key Financials
18.3.19.4. Sales Footprint
18.3.19.5. SWOT Analysis
18.3.19.6. Strategy Overview
18.3.19.6.1. Marketing Strategy
18.3.19.6.2. Product Strategy
18.3.19.6.3. Channel Strategy
18.3.20. Pentec Health
18.3.20.1. Overview
18.3.20.2. Product Portfolio
18.3.20.3. Key Financials
18.3.20.4. Sales Footprint
18.3.20.5. SWOT Analysis
18.3.20.6. Strategy Overview
18.3.20.6.1. Marketing Strategy
18.3.20.6.2. Product Strategy
18.3.20.6.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Parenteral Compounding Market
